Show simple item record

dc.contributor.authorJohnston, S
dc.contributor.authorKilburn, L
dc.contributor.authorEllis, P
dc.contributor.authorDodwell, D
dc.contributor.authorCameron, D
dc.contributor.authorHayward, L
dc.contributor.authorIm, Y-H
dc.contributor.authorBraybrooke, J
dc.contributor.authorBrunt, A
dc.contributor.authorCheung, K-L
dc.contributor.authorJyothirmayi, R
dc.contributor.authorRobinson, A
dc.contributor.authorWardley, Andrew M
dc.contributor.authorWheatley, D
dc.contributor.authorHowell, Anthony
dc.contributor.authorCoombes, G
dc.contributor.authorSergenson, N
dc.contributor.authorSin, H-J
dc.contributor.authorFolkerd, E
dc.contributor.authorDowsett, M
dc.contributor.authorBliss, J
dc.date.accessioned2013-10-29T12:06:01Z
dc.date.available2013-10-29T12:06:01Z
dc.date.issued2013-09
dc.identifier.citationFulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. 2013, 14 (10):989-98 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid23902874
dc.identifier.doi10.1016/S1470-2045(13)70322-X
dc.identifier.urihttp://hdl.handle.net/10541/304722
dc.description.abstractThe optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double endocrine targeting approach with the steroidal anti-oestrogen fulvestrant in combination with continued oestrogen deprivation.
dc.language.isoenen
dc.rightsArchived with thanks to The lancet oncologyen
dc.titleFulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.en
dc.typeArticleen
dc.contributor.departmentRoyal Marsden NHS Foundation Trust, London, UK. stephen.johnston@rmh.nhs.uken
dc.identifier.journalLancet Oncologyen
html.description.abstractThe optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double endocrine targeting approach with the steroidal anti-oestrogen fulvestrant in combination with continued oestrogen deprivation.


Files in this item

This item appears in the following Collection(s)

Show simple item record